Implicating androgen excess in propagating metabolic disease in polycystic ovary syndrome
Author(s)
Kempegowda, Punith
Melson, Eka
Manolopoulos, Konstantinos N
Arlt, Wiebke
O'Reilly, Michael W
Type
Journal Article
Abstract
Polycystic ovary syndrome (PCOS) has been traditionally perceived as a reproductive disorder due to its most common presentation with menstrual dysfunction and infertility. However, it is now clear that women with PCOS are at increased risk of metabolic dysfunction, from impaired glucose tolerance and type 2 diabetes mellitus to nonalcoholic fatty liver disease and cardiovascular disease. PCOS is characterised by androgen excess, with cross-sectional data showing that hyperandrogenism is directly complicit in the development of metabolic complications. Recent studies have also shown that C11-oxy C19 androgens are emerging to be clinically and biochemically significant in PCOS, thus emphasising the importance of understanding the impact of both classic and C11-oxy C19 androgens on women’s health. Here we discuss androgen metabolism in the context of PCOS, and dissect the role played by androgens in the development of metabolic disease through their effects on metabolic target tissues in women.
Date Issued
2020-01-01
Date Acceptance
2020-05-24
Citation
Therapeutic Advances in Endocrinology and Metabolism, 2020, 11
ISSN
2042-0188
Publisher
SAGE Publishing
Journal / Book Title
Therapeutic Advances in Endocrinology and Metabolism
Volume
11
Copyright Statement
© The Author(s), 2020. Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/32637065
PII: 10.1177_2042018820934319
Subjects
adipose tissue
androgens
BETA-CELL MASS
C11-oxy C19 androgens
CORONARY-ARTERY-DISEASE
diabetes
DIABETES-MELLITUS
Endocrinology & Metabolism
FATTY LIVER-DISEASE
IMPAIRED GLUCOSE-TOLERANCE
INCREASED 5-ALPHA-REDUCTASE ACTIVITY
INSULIN-RESISTANCE
Life Sciences & Biomedicine
metabolic disease
obesity
PCOS
REACTIVE PROTEIN-LEVELS
Science & Technology
SKELETAL-MUSCLE
VISCERAL ADIPOSITY INDEX
Publication Status
Published
Coverage Spatial
United States
Article Number
2042018820934319
Date Publish Online
2020-06-24